Navigation Links
Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
Date:11/1/2007

e same period in 2006. This was primarily due to a comparable decline in the US extended release carbamazepine prescription market.

Sales of CARBATROL for the three months to September 30, 2007 were $19.3 million, a decrease of 5% compared to the same period in 2006 (2006: $20.4 million). The sales decrease was in line with the decrease in prescriptions, as a sales price increase in April 2007 and wholesaler stocking during Q3 2007 were offset by higher sales deductions.

Patent litigation proceedings relating to CARBATROL are ongoing. Further information about this litigation can be found in our filings with the SEC, including our Annual Report on Form 10-K for the year to December 31, 2006.

XAGRID - Thrombocythemia

Sales for the three months to September 30, 2007 were $16.8 million, an increase of 26% compared to the same period in 2006 (2006: $13.3 million). Expressed in transaction currencies (XAGRID is primarily sold in Euros and Pounds sterling), sales increased by 17% due to growth in many of Shire's existing markets, with exchange rate movements against the US dollar accounting for the remaining 9% increase.

Human Genetic Therapies

REPLAGAL - Fabry disease

Sales for the three months to September 30, 2007 were $40.7 million, an increase of 26% compared to the same period in 2006 (2006: $32.4 million). Expressed in transaction currencies (REPLAGAL is primarily sold in Euros and Pounds sterling) sales increased by 18% due to higher unit sales in Europe and Canada, with exchange rate movements against the US dollar accounting for the remaining 8% increase.

ELAPRASE - Hunter syndrome

Sales for the three months to September 30, 2007 were $55.1 million (2006: $4.3 million). Q3 2007 sales represent a 29% increase over sales for Q2 2007 ($42.7 million). ELAPRASE was successfully launched in the US in August 2006 and in several major European markets during the first half of 2007. ELAPRASE is now approved for market
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Further support for use of statins in Alzheimer’s disease
2. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
3. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
4. NHS announces further Cost cutting Measures
5. NHS Recommends Further Cost Cutting Measures
6. Medha Patkars Condition Deteriorates Further
7. Oxford Radcliffe Hospitals Warns Of Further Job Losses
8. Asia Arming up to further the AIDS fight
9. Further Studies Needed To Completely Understand About Ventricular Fibrillation
10. Further improvements envisaged at Carstairs
11. UCLA Find Yields Further Insight into Causes of Parkinson’s Diseas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... following is a statement by Governor Lowell Weicker, Jr., ... President of the Board of the Trust for America,s ... Hamburg, MD, to serve as Commissioner of the Food ... as a TFAH Board Member for the past five-and-a-half ...
... involvement in health care recruiting and staffing. Individuals have the choice ... or working with an established Health Career Agents office. , ... ... Career Agents now has three ways for qualified individuals to get ...
... and futurist Ray Kurzweil , described by Forbes ... Sen. Tom Harkin (D-IA), health and wellness expert ... PepsiCo Senior Vice President and Chief Scientific Officer Dr. Mehmood ... March 16th conference on Race and Reconciliation in America: ...
... is underutilized in the U.S., expert says, , , FRIDAY, ... that people with chronic kidney disease, whether young or ... (AV) fistulas, surgically created passageways between veins and arteries ... , In calling AV fistulas the "gold standard of ...
... Plastic and Reconstructive Surgeon Kouros Azar, M.D. ... National Patient Safety Awareness Week from March 8 to 14, ... Massachusetts. Patient safety and comfort are paramount to Dr. ... foot state-of-the-art facilities located at 425 Haaland Drive, Suite 200 ...
... 1st new drug for disease in 50 years , , FRIDAY, ... offer the first new treatment approved for lupus in 50 ... College London. , The 22-month study included 20 people ... disease lupus. After treatment with Rituxan, 60 percent showed significant ...
Cached Medicine News:Health News:Appointment of Margaret Hamburg to Lead FDA Lauded by Gov. Lowell Weicker, President of the Board of Trust for America's Health 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 2Health News:Health Career Agents Announces Three Options for Involvement in Health Care Recruiting and Staffing 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 2Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 4Health News:Dialysis Via Fistulas May Help Young or Old 2Health News:Kouros Azar, M.D. (doctorazar.com), Noted Plastic and Reconstructive Surgeon, Offers Top 10 Tips to Patients to Help Celebrate National Patient Safety Awareness Week 2
(Date:1/23/2015)... baseball,s all-time hits leader, is the new spokesperson for the ... has announced. "Pete,s a Hall of Famer in ... board with Myoflex," said Ducere Pharma Chief Executive Officer ... known across all generations. The passion and intensity that Pete ...
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... According to Millennium Research Group (MRG), the global authority ... 2003 in Brazil, Russia, India, and China (BRIC) has ... astounding $500 billion spent in 2009 alone. One effect ... from MRG,s newest series of global diagnostic imaging reports ...
... Eclipsemed Ltd, a leading national supplier of advanced medical ... Human Med USA. Human Med AG of Germany, ... the revolutionary Body-Jet®, has formed Human Med USA to ... in the United States and North America. , ...
Cached Medicine Technology:$500 Billion Health Care Spend Boosts BRIC Countries' Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group 2$500 Billion Health Care Spend Boosts BRIC Countries' Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group 3Eclipse Announces Partnership with Human Med USA, Manufacturers of Revolutionary Body-Jet(R) 2
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
... test capability extending to 80, the M700 ... visual field, allowing peripheral defects that are ... be explored. Practice Management Integration provides the ... the Medmont Studio package the practitioner is ...
... The new software upgrade including fourSight ... Antares ultrasound system offers a wide variety ... added data management features that combine to ... challenges. , ,The Antares system was built ...
... stent technology with no compromises. It's the ... results. With S670's discrete, low-profile delivery system, ... excellent clinical results you want. S670, the ... compromises. It's the stent that delivers like ...
Medicine Products: